Precision medicine
research in Multiple Sclerosis:
what is on the horizon?

On December 2nd, 2020 we hosted a webinar to discuss precision medicine research in Multiple Sclerorsis in a fireside chat between Patrick Short, CEO of Sano Genetics, and Dr Mark Kotter, CEO of bit.bio - the award-winning human synthetic biology enterprise.

We talked about about Mark’s work running the company, alongside his role as an academic neurosurgeon at the University of Cambridge. The conversation ranged from stem cells and the effect they can have on neurodegenerative disease like Multiple Sclerosis, to the future of synthetic biology.